Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Hemolytic Anemia | Review

Manifestations of HbSE sickle cell disease: a systematic review

Authors: Ibrahim Khamees, Fateen Ata, Hassan Choudry, Ashraf T. Soliman, Vincenzo De Sanctis, Mohamed A. Yassin

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Sickle cell disease (SCD) is commonly encountered in Africa and Middle Eastern countries. The causative mutation in the gene encoding the hemoglobin subunit β (HBB) leads to various genotypic variants of the disease. This results in varied phenotypes, with a spectrum of complications, from benign to fatal. Hemoglobin SS (HBSS) genotype is associated with most of these complications; hence, it is a severe form of SCD. On the other hand, rare genotypes such as hemoglobin SE (HBSE) are considered benign. There is limited literature about the clinical manifestations and characteristics of patients with HBSE. We pooled all available data describing the phenotypic manifestations of HBSE heterozygote worldwide to perform a systematic review.

Methods

We performed a systematic review according to PRISMA guidelines using PubMed, SCOPUS, and Google Scholar databases. Two independent reviewers (FA and IK) evaluated studies for eligibility and extracted data. We synthesized data on demographics, manifestations, and management of HBSE disease. PROSPERO Registration Number: CRD42021229877.

Results

We found 68 HBSE patients reported in the literature. 24 cases were extracted from case reports whereas 44 cases from case series and retrospective studies. Turkey reported the highest number of patients (n = 22). 32 (47%) of the patients were males. The mean age was 20.9 ± 18.26 years. The mean HBS and HBE percentages were 61.1% ± 7.25% and 32.3% ± 5.06%, respectively, whereas the mean hemoglobin was 11.64 ± 1.73 g/dl. Reported manifestations of HBSE disease included acute vaso-occlusive pain crisis (n = 22, 32.3%), splenomegaly (n = 11, 16.1%), hemolytic anemia (n = 10, 14.7%), infections (n = 8. 11.7%), bone infarction (n = 4, 5.8%), gallstones (n = 3, 4.4%), venous thromboembolism (VTE) (n = 2, 2.9%) and stroke (n = 2, 2.9%), and hematuria (n = 2, 2.9%). Death due to HBSE complications was reported in three patients.

Conclusion

HBSE is a rare genotypic variant of SCD. It has been considered a benign form; however, there are multiple reports of severe complications. Severe complications observed in HBSE disease include vaso-occlusive crisis, acute chest syndrome, stroke, bone marrow embolism, and death.
Literature
1.
go back to reference Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14:263–92.PubMedCrossRef Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14:263–92.PubMedCrossRef
2.
go back to reference Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.PubMedCrossRef Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.PubMedCrossRef
3.
4.
go back to reference Wali Y, Kini V, Yassin MA. Distribution of sickle cell disease and assessment of risk factors based on transcranial Doppler values in the Gulf region. Hematology. 2020;25:55–62.PubMedCrossRef Wali Y, Kini V, Yassin MA. Distribution of sickle cell disease and assessment of risk factors based on transcranial Doppler values in the Gulf region. Hematology. 2020;25:55–62.PubMedCrossRef
5.
go back to reference Habara A, Steinberg MH. Minireview: genetic basis of heterogeneity and severity in sickle cell disease. Exp Biol Med. 2016;241:689–96.CrossRef Habara A, Steinberg MH. Minireview: genetic basis of heterogeneity and severity in sickle cell disease. Exp Biol Med. 2016;241:689–96.CrossRef
7.
go back to reference Knox-Macaulay HH, Ahmed MM, Gravell D, Al-Kindi S, Ganesh A. Sickle cell-haemoglobin E (HbSE) compound heterozygosity: a clinical and haematological study. Int J Lab Hematol. 2007;29:292–301.PubMedCrossRef Knox-Macaulay HH, Ahmed MM, Gravell D, Al-Kindi S, Ganesh A. Sickle cell-haemoglobin E (HbSE) compound heterozygosity: a clinical and haematological study. Int J Lab Hematol. 2007;29:292–301.PubMedCrossRef
9.
go back to reference Masiello D, Heeney MM, Adewoye AH, Eung SH, Luo HY, Steinberg MH, Chui DH. Hemoglobin SE disease: a concise review. Am J Hematol. 2007;82:643–9.PubMedCrossRef Masiello D, Heeney MM, Adewoye AH, Eung SH, Luo HY, Steinberg MH, Chui DH. Hemoglobin SE disease: a concise review. Am J Hematol. 2007;82:643–9.PubMedCrossRef
11.
12.
go back to reference Altay C, Niazi GA, Huisman TH. The combination of HB S and HB E in a black female. Hemoglobin. 1976;1:100–2.PubMedCrossRef Altay C, Niazi GA, Huisman TH. The combination of HB S and HB E in a black female. Hemoglobin. 1976;1:100–2.PubMedCrossRef
13.
go back to reference Andino L, Risin SA. Pathologic quiz case: a 24-year-old woman with abnormal hemoglobin and thrombocytopenia. Compound heterozygosity for hemoglobin S and E. Arch Pathol Lab Med. 2005;129:257–8.PubMedCrossRef Andino L, Risin SA. Pathologic quiz case: a 24-year-old woman with abnormal hemoglobin and thrombocytopenia. Compound heterozygosity for hemoglobin S and E. Arch Pathol Lab Med. 2005;129:257–8.PubMedCrossRef
14.
go back to reference Arbefeville EF, Tebbi CK, Chrostowski L, Adams VI. Sudden death after exercise in an adolescent with hemoglobin SE. Am J Forensic Med Pathol. 2011;32:341–3.PubMedCrossRef Arbefeville EF, Tebbi CK, Chrostowski L, Adams VI. Sudden death after exercise in an adolescent with hemoglobin SE. Am J Forensic Med Pathol. 2011;32:341–3.PubMedCrossRef
15.
go back to reference Baciu P, Yang C, Fantin A, Darnley-Fisch D, Desai U. First reported case of proliferative retinopathy in hemoglobin SE disease. Case Rep Ophthalmol Med. 2014;2014:782923.PubMedPubMedCentral Baciu P, Yang C, Fantin A, Darnley-Fisch D, Desai U. First reported case of proliferative retinopathy in hemoglobin SE disease. Case Rep Ophthalmol Med. 2014;2014:782923.PubMedPubMedCentral
16.
go back to reference Bird AR, Wood K, Leisegang F, Mathew CG, Ellis P, Hartley PS, Karabus CD. Haemoglobin E variants: a clinical, haematological and biosynthetic study of 4 South African families. Acta Haematol. 1984;72:135–7.PubMedCrossRef Bird AR, Wood K, Leisegang F, Mathew CG, Ellis P, Hartley PS, Karabus CD. Haemoglobin E variants: a clinical, haematological and biosynthetic study of 4 South African families. Acta Haematol. 1984;72:135–7.PubMedCrossRef
17.
go back to reference Eichhorn RF, Buurke EJ, Blok P, Berends MJ, Jansen CL. Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E. J Intern Med. 1999;245:103–6.PubMedCrossRef Eichhorn RF, Buurke EJ, Blok P, Berends MJ, Jansen CL. Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E. J Intern Med. 1999;245:103–6.PubMedCrossRef
18.
19.
go back to reference Ganesh A, al-Habsi NS, al-Alawi FK, Mitra S, Eriksson A, Venugopalan P. Traumatic hyphaema and sickle cell retinopathy in a patient with sickle cell-haemoglobin E (HbSE) disease. Eye. 2000;14(3):397–400.PubMedCrossRef Ganesh A, al-Habsi NS, al-Alawi FK, Mitra S, Eriksson A, Venugopalan P. Traumatic hyphaema and sickle cell retinopathy in a patient with sickle cell-haemoglobin E (HbSE) disease. Eye. 2000;14(3):397–400.PubMedCrossRef
20.
go back to reference George E, Iqbal QM. Hb ES presenting as avascular necrosis. Southeast Asian J Trop Med Public Health. 1978;9:568–70.PubMed George E, Iqbal QM. Hb ES presenting as avascular necrosis. Southeast Asian J Trop Med Public Health. 1978;9:568–70.PubMed
21.
go back to reference Gupta R, Jarvis M, Yardumian A. Compound heterozygosity for haemoglobin S and haemoglobin E. Br J Haematol. 2000;108:463.PubMedCrossRef Gupta R, Jarvis M, Yardumian A. Compound heterozygosity for haemoglobin S and haemoglobin E. Br J Haematol. 2000;108:463.PubMedCrossRef
22.
go back to reference Gürkan E. Vaso-occlusive manifestations in a patient with sickle cell-hemoglobin E (HbSE) disease. Am J Hematol. 2006;81:149.PubMedCrossRef Gürkan E. Vaso-occlusive manifestations in a patient with sickle cell-hemoglobin E (HbSE) disease. Am J Hematol. 2006;81:149.PubMedCrossRef
23.
go back to reference Hardy MJ, Ragbeer MS. Homozygous HbE and HbSE disease in a Saudi family. Hemoglobin. 1985;9:47–52.PubMedCrossRef Hardy MJ, Ragbeer MS. Homozygous HbE and HbSE disease in a Saudi family. Hemoglobin. 1985;9:47–52.PubMedCrossRef
24.
go back to reference Italia K, Upadhye D, Dabke P, Kangane H, Colaco S, Sawant P, Nadkarni A, Gorakshakar A, Jain D, Italia Y, et al. Clinical and hematological presentation among Indian patients with common hemoglobin variants. Clin Chim Acta. 2014;431:46–51.PubMedCrossRef Italia K, Upadhye D, Dabke P, Kangane H, Colaco S, Sawant P, Nadkarni A, Gorakshakar A, Jain D, Italia Y, et al. Clinical and hematological presentation among Indian patients with common hemoglobin variants. Clin Chim Acta. 2014;431:46–51.PubMedCrossRef
26.
go back to reference Mishra P, Pati HP, Chatterjee T, Dixit A, Choudhary DR, Srinivas MU, Mahapatra M, Choudhry VP. Hb SE disease: a clinico-hematological profile. Ann Hematol. 2005;84:667–70.PubMedCrossRef Mishra P, Pati HP, Chatterjee T, Dixit A, Choudhary DR, Srinivas MU, Mahapatra M, Choudhry VP. Hb SE disease: a clinico-hematological profile. Ann Hematol. 2005;84:667–70.PubMedCrossRef
27.
go back to reference Mukhopadhyay S, Kumar N, Saxena R. Sickle cell-hemoglobin E disease in an Indian family. Indian J Pathol Microbiol. 2001;44:465–6.PubMed Mukhopadhyay S, Kumar N, Saxena R. Sickle cell-hemoglobin E disease in an Indian family. Indian J Pathol Microbiol. 2001;44:465–6.PubMed
28.
go back to reference Pajak A, Li JC, Liu A, Nazare S, Smith B. Hemoglobin SE disease presenting as a high-altitude massive splenic infarction complicated by hemorrhagic conversion and splenectomy. Cureus. 2020;12:e10321.PubMedPubMedCentral Pajak A, Li JC, Liu A, Nazare S, Smith B. Hemoglobin SE disease presenting as a high-altitude massive splenic infarction complicated by hemorrhagic conversion and splenectomy. Cureus. 2020;12:e10321.PubMedPubMedCentral
29.
go back to reference Ramahi AJ, Lewkow LM, Dombrowski MP, Bottoms SF. Sickle cell E hemoglobinopathy and pregnancy. Obstet Gynecol. 1988;71:493–5.PubMed Ramahi AJ, Lewkow LM, Dombrowski MP, Bottoms SF. Sickle cell E hemoglobinopathy and pregnancy. Obstet Gynecol. 1988;71:493–5.PubMed
30.
go back to reference Rayburg M, Kalinyak KA, Towbin AJ, Baker PB, Joiner CH. Fatal bone marrow embolism in a child with hemoglobin SE disease. Am J Hematol. 2010;85:182–4.PubMed Rayburg M, Kalinyak KA, Towbin AJ, Baker PB, Joiner CH. Fatal bone marrow embolism in a child with hemoglobin SE disease. Am J Hematol. 2010;85:182–4.PubMed
31.
go back to reference Rey KS, Unger CA, Rao SP, Miller ST. Sickle cell-hemoglobin E disease: clinical findings and implications. J Pediatr. 1991;119:949–51.PubMedCrossRef Rey KS, Unger CA, Rao SP, Miller ST. Sickle cell-hemoglobin E disease: clinical findings and implications. J Pediatr. 1991;119:949–51.PubMedCrossRef
32.
go back to reference Schroeder WA, Powars D, Reynolds RD, Fisher JI. Hb-E in combination with Hb-S and Hb-C in a black family. Hemoglobin. 1977;1:287–9.PubMedCrossRef Schroeder WA, Powars D, Reynolds RD, Fisher JI. Hb-E in combination with Hb-S and Hb-C in a black family. Hemoglobin. 1977;1:287–9.PubMedCrossRef
34.
go back to reference Tamminga RY, Doornbos ME, Muskiet FA, Koetse HA. Rhabdomyolysis in a child with hemoglobin SE. Pediatr Hematol Oncol. 2012;29:267–9.PubMedCrossRef Tamminga RY, Doornbos ME, Muskiet FA, Koetse HA. Rhabdomyolysis in a child with hemoglobin SE. Pediatr Hematol Oncol. 2012;29:267–9.PubMedCrossRef
35.
go back to reference Tay SH, Teng GG, Poon M, Lee VK, Lim AY. A case of hemoglobin SE presenting with sickle cell crisis: case report and histological correlation. Ann Acad Med Singap. 2011;40:552–3.PubMed Tay SH, Teng GG, Poon M, Lee VK, Lim AY. A case of hemoglobin SE presenting with sickle cell crisis: case report and histological correlation. Ann Acad Med Singap. 2011;40:552–3.PubMed
36.
go back to reference Thornburg CD, Steinberg MH, Chui DH. Hemoglobin SE disease in Maine, and severe thalassemia in New Hampshire. J Pediatr Hematol Oncol. 2009;31:307.PubMedCrossRef Thornburg CD, Steinberg MH, Chui DH. Hemoglobin SE disease in Maine, and severe thalassemia in New Hampshire. J Pediatr Hematol Oncol. 2009;31:307.PubMedCrossRef
37.
go back to reference Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2016;376:429–39.PubMedPubMedCentralCrossRef Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2016;376:429–39.PubMedPubMedCentralCrossRef
38.
go back to reference Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381:509–19.PubMedCrossRef Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381:509–19.PubMedCrossRef
39.
go back to reference Orkin SH, Bauer DE. Emerging genetic therapy for sickle cell disease. Annu Rev Med. 2019;70:257–71.PubMedCrossRef Orkin SH, Bauer DE. Emerging genetic therapy for sickle cell disease. Annu Rev Med. 2019;70:257–71.PubMedCrossRef
40.
go back to reference Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M, Aromataris E. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127–33.PubMedCrossRef Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M, Aromataris E. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127–33.PubMedCrossRef
41.
go back to reference Matthews DC, Glader B. Erythrocyte disorders in infancy. In: Gleason CA, Devaskar SU, editors. Avery’s diseases of the newborn. 9th ed. Philadelpia: W.B. Saunders; 2012. p. 1080–107.CrossRef Matthews DC, Glader B. Erythrocyte disorders in infancy. In: Gleason CA, Devaskar SU, editors. Avery’s diseases of the newborn. 9th ed. Philadelpia: W.B. Saunders; 2012. p. 1080–107.CrossRef
42.
go back to reference Hurley R. Anemia and red blood cell disorders. In: Walker PF, Barnett ED, editors. Immigrant medicine. Edinburgh: W.B. Saunders; 2007. p. 611–23.CrossRef Hurley R. Anemia and red blood cell disorders. In: Walker PF, Barnett ED, editors. Immigrant medicine. Edinburgh: W.B. Saunders; 2007. p. 611–23.CrossRef
43.
go back to reference Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79:704–12.PubMedPubMedCentral Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79:704–12.PubMedPubMedCentral
44.
go back to reference Quinn CT. Minireview: clinical severity in sickle cell disease: the challenges of definition and prognostication. Exp Biol Med. 2016;241:679–88.CrossRef Quinn CT. Minireview: clinical severity in sickle cell disease: the challenges of definition and prognostication. Exp Biol Med. 2016;241:679–88.CrossRef
45.
go back to reference Chang AK, Ginter Summarell CC, Birdie PT, Sheehan VA. Genetic modifiers of severity in sickle cell disease. Clin Hemorheol Microcirc. 2018;68:147–64.PubMedCrossRef Chang AK, Ginter Summarell CC, Birdie PT, Sheehan VA. Genetic modifiers of severity in sickle cell disease. Clin Hemorheol Microcirc. 2018;68:147–64.PubMedCrossRef
46.
go back to reference Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, et al. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation. 2011;124:1452–60.PubMedPubMedCentralCrossRef Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, et al. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation. 2011;124:1452–60.PubMedPubMedCentralCrossRef
47.
go back to reference Vishwanathan C, Agarwal MB, Bichile LS, Bhave AB. Double heterozygosity for hemoglobin S and E. Indian Pediatr. 1992;29:895–7.PubMed Vishwanathan C, Agarwal MB, Bichile LS, Bhave AB. Double heterozygosity for hemoglobin S and E. Indian Pediatr. 1992;29:895–7.PubMed
Metadata
Title
Manifestations of HbSE sickle cell disease: a systematic review
Authors
Ibrahim Khamees
Fateen Ata
Hassan Choudry
Ashraf T. Soliman
Vincenzo De Sanctis
Mohamed A. Yassin
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02931-1

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.